- Clinical stage biopharmaceutical company Acurx Pharmaceuticals (NASDAQ:ACXP) has priced its IPO of 2.5M newly-issued common shares at $6.00/share, for expected gross proceeds of ~$15M.
- Underwriters have been granted a 45-day option to buy up to an additional 375,000 common shares.
- Closing date is June 29, 2021.
- Proceeds from the offering will be used to complete pre-clinical development of ACX-375C, complete the Phase 2b clinical trial of ibezapolstat in patients with Clostridium difficile Infections and for general corporate purposes.
- In a recent analysis, SA contributor Donovan Jones talked about the IPO and stated that, "ACXP is a promising firm but is still at an early stage and the IPO may be more relevant for long-term hold institutional investors."
- Press Release
Acurx Pharmaceuticals prices $15M IPO
Recommended For You
More Trending News
About ACXP Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ACXP | - | - |
Acurx Pharmaceuticals, Inc. |